capecitabine + eribulin + gemcitabine + paclitaxel + nab-paclitaxel

This is a combination regimen consisting of five chemotherapeutic agents—capecitabine, eribulin, gemcitabine, paclitaxel, and nab-paclitaxel. Each drug has a distinct mechanism of action targeting cancer cell proliferation and survival: - **Capecitabine** is an oral prodrug that is converted to 5-fluorouracil (5-FU) in the body. 5-FU inhibits thymidylate synthase, disrupting DNA synthesis. - **Eribulin** is a microtubule dynamics inhibitor that binds to the growing ends of microtubules and prevents their elongation, leading to mitotic blockade. - **Gemcitabine** is a nucleoside analog that incorporates into DNA during replication and inhibits ribonucleotide reductase, resulting in inhibition of DNA synthesis and apoptosis. - **Paclitaxel** stabilizes microtubules by binding to β-tubulin subunits; this prevents normal microtubule disassembly required for cell division, causing mitotic arrest[4][7]. - **Nab-paclitaxel (nanoparticle albumin-bound paclitaxel)** uses albumin as a delivery vehicle for paclitaxel; it shares the same mechanism as paclitaxel but offers improved solubility and altered pharmacokinetics[6]. This combination would be considered highly experimental or investigational as there are no standard regimens using all five drugs together. Each agent individually or in smaller combinations is approved for various solid tumors such as breast cancer, pancreatic cancer (notably nab-paclitaxel with gemcitabine), non-small cell lung cancer (NSCLC), ovarian cancer, among others[2][6][8]. The use of all five together would likely be limited to clinical trials or specific research protocols.

Other names

cyclophosphamide → paclitaxelcyclophosphamide followed by paclitaxel